Investigation of suramin-albumin binding by electrospray mass spectrometry.
Suramin, an organic polyanion with six sulphonic groups, is under clinical trials as an agent against hormone-refractory prostate cancer. The drug binds strongly to serum albumin. The objectives were to use electrospray to measure the molecular masses of the intact complexes of albumin and suramin to determine the number of suramin molecules bound under different molar ratios, and to investigate the binding of suramin in human serum. With albumin in excess (2:1 to 25:1 ratio), only 1 and 2 bound suramins were found; with suramin excess (2:1 to 1000:1) up to 20 bound suramin molecules/albumin were found. Up to 5 bound suramins were found in human serum with 4:1 suramin:albumin ratio, which corresponds to recommended therapeutic doses (200-300 micrograms/mL). At 8:1 ratio, which would be toxic, complexes with up to ten bound suramin molecules were found, and unreacted albumin diminished.
Division of Neoplastic Diseases, Mount Sinai School of Medicine New York, NY 10029, USA.
J
J
Roboz
L
L
Deng
L
L
Ma
J F
JF
Holland
D006801:Humans; D013058:Mass Spectrometry; D011485:Protein Binding; D012709:Serum Albumin / Q000737:chemistry*; D013498:Suramin / Q000737:chemistry*; D014344:Trypanocidal Agents / Q000737:chemistry*
D012709:Serum Albumin; D014344:Trypanocidal Agents; D013498:Suramin